Plandai Biotechnology's Move Into Medical Marijuana Research Gets Validation With New Study

NEW YORK, NY--(Marketwired - Nov 14, 2013) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) and its subsidiary, Cannabis Biosciences, Inc., received a strong validation for their move into medical marijuana research from a recently published study. Plandaí formed its marijuana subsidiary for the purpose of developing and testing a new Phytofare™ botanical extract derived from cannabis. 

The validation comes in the form of a new study done by a team at St. George's, University of London and published in the journal Anticancer Research. Dr. Wai Liu and his colleagues carried out laboratory investigations that used a number of cannabinoids, either alone or in combination with each other, to measure their anti-cancer actions in relation to leukemia.

Plandaí would be working with cannabinoids in its research. The company says that during the extraction process of the cannabis leaf using its hydrodynamic sheering technology, it can remove the psychoactive compound tetrahydrocannabinol (THC) which would allow it to focus on and enhance the cannabinoids. By removing the THC, the subsidiary can render a botanical drug that offers many of the medicinal benefits of cannabis without the perceived negative side effects and social stigma. 

The team studied six cannabinoids and each demonstrated anti-cancer properties as effective as those seen with THC, and, of note, they found the cannabinoids had an increased effect on cancer cells when combined with each other. Plandaí's proposed extract would be a compound of all active phyto-cannabinoids, less THC, so it's potential as an anti-cancer agent is compelling.

This group's research has shown that the non-hallucinogenic components of cannabis can act as effective anti-cancer agents. The anti-cancer properties of THC have been recognized for many years, but research into similar cannabis-derived compounds has been somewhat limited.

Dr Liu who led the team of researchers said, "This study is a critical step in unpicking the mysteries of cannabis as a source of medicine. The cannabinoids examined have minimal, if any, hallucinogenic side effects, and their properties as anti-cancer agents are promising.

"These agents are able to interfere with the development of cancerous cells, stopping them in their tracks and preventing them from growing. In some cases, by using specific dosage patterns, they can destroy cancer cells on their own."

About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, Interviews and Feature Articles. For more information: www.stockmarketmediagroup.com